Johan Hansson focuses on Melanoma, Genetics, Cancer research, Internal medicine and Molecular biology. The study incorporates disciplines such as Mutation, Gene, Immunology, Pathology and CD14 in addition to Melanoma. Johan Hansson has included themes like Carcinogenesis, Cancer, Cyclin D1 and Exon in his Cancer research study.
The Internal medicine study combines topics in areas such as Gastroenterology, Surgery and Oncology. His work investigates the relationship between Surgery and topics such as Trametinib that intersect with problems in Phases of clinical research and Hazard ratio. His Molecular biology study incorporates themes from Cell culture, Cytotoxic T cell, T cell, Antigen-presenting cell and Lymphokine-activated killer cell.
His primary areas of investigation include Melanoma, Cancer research, Internal medicine, Oncology and Genetics. As a member of one scientific family, Johan Hansson mostly works in the field of Melanoma, focusing on Immunology and, on occasion, Cytotoxic T cell. His research investigates the connection with Cancer research and areas like Cell culture which intersect with concerns in Molecular biology.
The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His Oncology research is multidisciplinary, incorporating perspectives in Survival analysis and Chemotherapy, Phases of clinical research. His studies deal with areas such as Odds ratio and Proportional hazards model as well as Hazard ratio.
Johan Hansson mostly deals with Melanoma, Cancer research, Internal medicine, Oncology and Nivolumab. His research in Melanoma intersects with topics in Cancer, Targeted therapy, Immunotherapy, Progression-free survival and Peripheral blood mononuclear cell. His research integrates issues of Genetic heterogeneity and Crizotinib in his study of Cancer research.
Internal medicine and Cutaneous melanoma are frequently intertwined in his study. His Oncology research incorporates themes from Germline mutation, Pancreatic cancer, Phases of clinical research, Genetic testing and Receiver operating characteristic. He usually deals with Nivolumab and limits it to topics linked to Pembrolizumab and Myeloid-derived Suppressor Cell, Chromatin remodeling and Metastasis.
Johan Hansson mostly deals with Melanoma, Cancer research, Internal medicine, Oncology and Targeted therapy. His study in the field of Cutaneous melanoma also crosses realms of Afatinib. His Cutaneous melanoma study combines topics from a wide range of disciplines, such as Odds ratio, Progression-free survival, Microvesicles, microRNA and Hazard ratio.
His work carried out in the field of Cancer research brings together such families of science as Downregulation and upregulation, Immune system, Intratumoral Genetic Heterogeneity, Tumor progression and Regulation of gene expression. His Oncology study integrates concerns from other disciplines, such as Symptom severity, Quality of life and Phases of clinical research. His Targeted therapy research integrates issues from Cell cycle, Crizotinib and Insulin-like growth factor 1 receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko.
The New England Journal of Medicine (2014)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko.
The Lancet (2015)
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
Thorunn Rafnar;Patrick Sulem;Simon N Stacey;Frank Geller.
Nature Genetics (2009)
Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma
D. Timothy Bishop;Florence Demenais;Alisa M. Goldstein;Wilma Bergman.
Journal of the National Cancer Institute (2002)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid;Henrik Schmidt;Aviram Nissan;Laura Ridolfi.
Journal of Translational Medicine (2011)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas.
Annals of Oncology (2017)
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Shahab Akhoondi;Dahui Sun;Natalie von der Lehr;Sophia Apostolidou.
Cancer Research (2007)
Genome-wide association study identifies three loci associated with melanoma risk.
D Timothy Bishop;Florence Demenais;Mark M Iles;Mark Harland.
Nature Genetics (2009)
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Katarina Omholt;Anton Platz;Lena Kanter;Ulrik Ringborg.
Clinical Cancer Research (2003)
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity.
Koji Kono;Flavio Salazar-Onfray;Max Petersson;Johan Hansson.
European Journal of Immunology (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: